Initial

Nick Armstrong Named CAI's Initial Senior Director of Digital Enablement

Retrieved on: 
Friday, February 3, 2023
Personal care, Human, Process, North Carolina State University, Smarter Agent, Inc., Biopharmaceutical, National Center for Manufacturing Sciences, Engineering, Culture, Master of Science, Bioprocess engineering, CAI, Facility management, Growth, Initial, Digital transformation, Nursing, Management, Reliability, Food

INDIANAPOLIS, Feb. 3, 2023 /PRNewswire/ -- Commissioning Agents Inc. (CAI) announced  Nick Armstrong has been named the Initial Senior Director of Digital Enablement, as CAI continues our investment in Digital Transformation for both our internal programs and our clients' operations.

Key Points: 
  • INDIANAPOLIS, Feb. 3, 2023 /PRNewswire/ -- Commissioning Agents Inc. (CAI) announced  Nick Armstrong has been named the Initial Senior Director of Digital Enablement, as CAI continues our investment in Digital Transformation for both our internal programs and our clients' operations.
  • Mr. Armstrong has 15 years of experience in the Biopharmaceutical, Food, and Personal Care industries – with innovation and digital enablement as the throughline.
  • The supply chain and regulatory complexities for this mission require a connected voice", Mr. Armstrong Nick explained.
  • "I'm excited to have Nick join the technology team and for the official establishment of Director of Digital Enablement role," stated Jackie Karceski, Chief Technology Officer of CAI.

Settlement agreement reached for Gottfriedson Band class

Retrieved on: 
Saturday, January 21, 2023
Four Pillars, History, Grand Council of the Crees, Government, Language, Hold Still: A Portrait of Our Nation in 2020, Initial, Residential school, Court, Minister of Crown–Indigenous Relations, Culture, Federal Court (Canada), News, Walking, Federal court, Room and pillar mining, Partnership, Nation, Inuktitut, Indigenous peoples, Grand Council, Survivor, Cree, First Nations, Hope, Genocide, Residential care, Insurance, Tourism

VANCOUVER, BC, Jan. 21, 2023 /CNW/ - Today, Band class representatives former Chief Shane Gottfriedson and former Chief Garry Feschuk, along with the Honourable Marc Miller, Minister of Crown-Indigenous Relations, announced that Canada has signed an agreement with the Representative Plaintiffs who represent the 325 members that have opted into the Gottfriedson Band class litigation.

Key Points: 
  • VANCOUVER, BC, Jan. 21, 2023 /CNW/ - Today, Band class representatives former Chief Shane Gottfriedson and former Chief Garry Feschuk, along with the Honourable Marc Miller, Minister of Crown-Indigenous Relations, announced that Canada has signed an agreement with the Representative Plaintiffs who represent the 325 members that have opted into the Gottfriedson Band class litigation.
  • Each Band class member will receive a share of annual investment income that is available.
  • The Court will consider whether the settlement is fair, reasonable and in the best interest of the class members.
  • Together, we have developed a settlement that will support the Band class members in their healing journeys for generations to come."

Acerus Files For CCAA Protection

Retrieved on: 
Thursday, January 26, 2023
W.F. Young, Inc., Ontario Superior Court of Justice, United States bankruptcy court, TSX, Toronto Stock Exchange, CCAA, ASP, Initial, Health Management Associates (Florida company), Chapter 15, Title 11, United States Code, Monitor, Bankruptcy, Bankruptcy Code, Security (finance), Financial adviser, Pristimantis acerus

TORONTO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that the Company and its subsidiaries, Acerus Biopharma Inc., Acerus Labs Inc. and Acerus Pharmaceuticals USA, LLC (collectively, the “Acerus Group”), have received an order for creditor protection (the “Initial Order”) from the Ontario Superior Court of Justice (Commercial List) (the “Court”) under the Companies’ Creditors Arrangement Act (the “CCAA”).

Key Points: 
  • TORONTO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that the Company and its subsidiaries, Acerus Biopharma Inc., Acerus Labs Inc. and Acerus Pharmaceuticals USA, LLC (collectively, the “Acerus Group”), have received an order for creditor protection (the “Initial Order”) from the Ontario Superior Court of Justice (Commercial List) (the “Court”) under the Companies’ Creditors Arrangement Act (the “CCAA”).
  • The Acerus Group sought creditor protection under the CCAA in order to receive a stay of proceedings that will allow the Acerus Group to work with the Monitor to facilitate the development of an orderly process designed to maximize the value of the Acerus Group’s assets, for the benefit of its creditors and other stakeholders.
  • The DIP Loan (as described below) is anticipated to fund the operations of the Acerus Group in the ordinary course during this process.
  • The Acerus Group intends to also file petitions commencing proceedings under Chapter 15 of the United States Bankruptcy Code at the United States Bankruptcy Court for the District of Delaware for creditor protection in the United States.

VERSES Receives Acceptance from NEO Exchange for Warrant Listing

Retrieved on: 
Monday, January 23, 2023
SEDAR, NEO, Initial, Endeavour, Security (finance)

An aggregate of 11,613,485 Class A Warrants (the “Amended Warrants”) were subject to certain Warrant Amendments (as defined and described in the Initial Press Release).

Key Points: 
  • An aggregate of 11,613,485 Class A Warrants (the “Amended Warrants”) were subject to certain Warrant Amendments (as defined and described in the Initial Press Release).
  • The Amended Warrants will be posted for trading on the NEO at market open on January 24, 2023 under the symbol “VERS.WT.A”.
  • An aggregate of 6,487,229 Class A Warrants (the “Unlisted Warrants”) may become listed on the NEO once the Company’s receives written consent from the applicable warrant holders for the Warrant Amendments.
  • Prior to the Company listing a new batch of Unlisted Warrants after the initial Supplemental Listing, the Company will file a NEO Form 14A – Notice of an Additional Listing with the NEO.

Blackrock Silver Enters into Option Agreement with Tearlach Resources to Develop the Tonopah North Lithium Project

Retrieved on: 
Tuesday, January 10, 2023
Lithium, Cloud, Additive manufacturing file format, Option style, News, Silver, Initial, Second Optional Protocol to the International Covenant on Civil and Political Rights, International joint venture, First Option, South Tyrol Option Agreement, Joint venture, TEA, BRC, Smart contract, Growth, Option, Engineering, Feasibility, Mineral, Sale, National instrument, Gold, Exercise, Motor vehicle, Rolls-Royce Silver Cloud

Information concerning the discovery of lithium during the Company's first exploration drill program on the Tonopah North Project was announced in the Company's news release dated October 25, 2022.

Key Points: 
  • Information concerning the discovery of lithium during the Company's first exploration drill program on the Tonopah North Project was announced in the Company's news release dated October 25, 2022.
  • The exploration and development rights conferred to Tearlach under the Option Agreement in respect of the Tonopah North Project are exclusive to lithium minerals in the Optioned Zone.
  • Subject to the terms of the Option Agreement, Blackrock retains and reserves the rights to explore for, develop and mine all minerals (including gold and silver) other than lithium on the entire Tonopah North Project, including the Optioned Zone.
  • Upon Tearlach completing the Initial Earn-In and exercising the First Option, Tearlach and Blackrock Gold shall enter into a definitive mining joint venture agreement (the "Joint Venture Agreement") in respect of the management and ownership of the Optioned Zone of the Tonopah North Project (the "Joint Venture").

Tearlach Enters Into a Joint Venture Agreement With Blackrock Silver to Develop the Tonopah North Lithium Project, Nevada

Retrieved on: 
Tuesday, January 10, 2023
Lithium, Additive manufacturing file format, Option style, TLC, Initial, Second Optional Protocol to the International Covenant on Civil and Political Rights, RC, International joint venture, OTC, First Option, TSX Venture Exchange, South Tyrol Option Agreement, Joint venture, Exercise, TEA, BRC, Smart contract, Silver, Growth, Option, Black Rock, V44, Engineering, Mineral, Sale, Policy, National instrument, Gold, Motor vehicle

Morgan Lekstrom, CEO of Tearlach, commented, “This is a significant growth step for Tearlach in becoming a leading multijurisdictional lithium company and for Blackrock Silver diversifying their already world-class silver project.

Key Points: 
  • Morgan Lekstrom, CEO of Tearlach, commented, “This is a significant growth step for Tearlach in becoming a leading multijurisdictional lithium company and for Blackrock Silver diversifying their already world-class silver project.
  • Upon Tearlach completing the Initial Earn-In and exercising the First Option, Tearlach and Blackrock Gold shall enter into a definitive mining joint venture agreement (the “Joint Venture Agreement”) in respect of the management and ownership of the Optioned Zone of the Tonopah North Project (the “Joint Venture”).
  • The parties to the Joint Venture shall contribute to future Expenditures in accordance with their respective participating interests as prescribed in the Joint Venture Agreement.
  • Subject to the terms of the Joint Venture Agreement, Tearlach shall be the initial manager of the Joint Venture and shall have control of the activities and operations of the Joint Venture.

G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib

Retrieved on: 
Monday, January 9, 2023
PARK, Trilaciclib, Control, Toxicity, Overalls, Prognosis, OS, Bevacizumab, Febrile neutropenia, Anemia, CRC, Therapy, PFS, DMC, Neutropenia, Response evaluation criteria in solid tumors, Grade 3, FOLFOXIRI, MUC, Colorectal cancer, Safety, FDA, Aplastic anemia, Risk, Thrombocytopenia, Data monitoring committee, Tumor microenvironment, Carboplatin, Maintenance, GC, TNBC, Survival, Patient, Bone marrow, Chain reaction, Pivotal, RESEARCH, Avelumab, Diarrhea, Pharmaceutical industry, Fine chemical, Medical imaging, Initial

RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the 2023 data readouts that are expected to drive its near-term and long-term indications and potential future treatment paradigms for some of the most aggressive and refractory cancers, including metastatic colorectal (mCRC), bladder or urothelial cancer (mUC), and triple negative breast cancer (TNBC).

Key Points: 
  • “But the high toxicity of these cytotoxic agents poses a risk of serious adverse events that can compromise patient well-being and patient outcomes.
  • Depending on the tumor type and the chemotherapy backbone, this mechanistic profile can drive patient benefits of myeloprotection and/or anti-tumor efficacy.
  • Initial results provided in January 2023 indicate that the confirmed objective response rate as of the cutoff date was comparable between arms.
  • G1 expects to release initial PFS data from PRESERVE 1 on the combination of trilaciclib administered prior to FOLFOXIRI and bevacizumab in 4Q23.

Sail Into Web3 With the Crypto Ark: Bybit Looks Ahead in Year End Keynote Address

Retrieved on: 
Sunday, January 22, 2023
Crypto, Ecosystem, Marketing, Partnership, MIBR, CeX (company), Merkle tree, Iđoš, MPC, TPS, F1, Initial, Astralis, API, Non-fungible token, Fiat, Circle, Formula, 2012 Abu Dhabi Grand Prix, Spot–future parity, USDT, NFT, NAVI, Trust, Web3, Very important person, Paradigm, USDC, DEX, CEX, Abu Dhabi Grand Prix, Cryptocurrency, Security (finance), Video game, Spot, Option, Unified, Bybit Lydia Tsomondo

Sail Into Web3 With the Crypto Ark: Bybit Looks Ahead in Year End Keynote Address

Key Points: 
  • Sail Into Web3 With the Crypto Ark: Bybit Looks Ahead in Year End Keynote Address
    Sail Into Web3 With the Crypto Ark: Bybit Looks Ahead in Year End Keynote Address
    Dubai, United Arab Emirates | January 05, 2023 08:45 AM Eastern Standard Time
    Ben Zhou, co-founder and CEO of Bybit, the third most visited cryptocurrency exchange in the world, shared Bybit's journey in becoming a Crypto Ark and a gateway to empower users to level up to Web3 in a candid exchange at a virtual event last week.
  • In a rollercoaster year that saw many peees succumb to market adversity, Bybit delivered its “Best 10”:
    Brand 3.0 for Web 3.0.
  • Over half a million new users started their crypto journey on Bybit with the exchange’s zero fees campaign in 2022.
  • He said the idea behind Bybit's Web3 push was to enable users to explore more with fewer clicks, starting with the Bybit Web3 Wallet.

XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Saturday, January 7, 2023
Initial, Amend, Inducement rule, Employment, Pharmaceutical industry

The First Hughes Inducement Award will vest in a series of four equal installments on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023.

Key Points: 
  • The First Hughes Inducement Award will vest in a series of four equal installments on March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023.
  • The Second Hughes Inducement Award will vest in a series of 36 successive equal monthly installments measured from January 1, 2023.
  • The Inducement Awards are subject to the terms and conditions of the Company's Amended and Restated 2010 Long Term Incentive and Stock Award Plan but were granted outside the plan as an inducement material to each of Mr. Hughes and Mr. Sitko entering into employment with XOMA in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Inducement Awards also have a ten-year term and are each subject to the terms and conditions of the stock option agreement pursuant to which each such Inducement Award was granted.

Worldwide Nasopharyngeal Cancer Industry to 2028 - North America is the Fastest Growing Region - ResearchAndMarkets.com

Retrieved on: 
Friday, January 6, 2023
Pharmaceutical, Health, Oncology, EBRT, Hearing loss, Bone, Adenocarcinoma, MRI, Headache, IARC, Megasphaera, Woman, Tobacco, Severe acute respiratory syndrome coronavirus 2, MEA, American Institute, Initial, Squamous cell carcinoma, COVID-19, Organic, Pharynx, News, Immunotherapy, Brachytherapy, Research, Nasopharyngeal carcinoma, Growth, Patient, CT, Chemoradiotherapy, Weight loss, PET, Fatigue, Blurred, Hypoesthesia, Neck, Prevalence, Diagnosis, NPC, Cell, Dietary supplement, Pharmaceutical industry, Medical imaging, Marketing, Cancer

The symptoms of nasopharyngeal cancer include a lump in the neck, hearing loss, stuffiness, numbness, frequent headaches, fatigue, blurred, weight loss etc.

Key Points: 
  • The symptoms of nasopharyngeal cancer include a lump in the neck, hearing loss, stuffiness, numbness, frequent headaches, fatigue, blurred, weight loss etc.
  • According to the American Institute for Cancer Research estimates, Nasopharyngeal cancer is the 23rd most common cancer worldwide, and it is the 18th most commonly occurring cancer in men and the 22nd most commonly occurring cancer in women.
  • Thus, the high prevalence rate of nasopharyngeal cancer will increase the demands for effective drugs and therapies that will further lead to market growth.
  • The global nasopharyngeal cancer market is segmented based on cancer type, diagnosis method, and therapy.